ASB20123, a C-type natriuretic peptide/ghrelin chimeric peptide, was designed as a 22 novel peptide and demonstrated full agonistic activity for natriuretic-peptide receptor B and a 23 significantly longer half-life in plasma compared with the native peptide. We researched the 24 toxicological profile of ASB20123, the correlation between the morphological change of the 25 epiphyseal plate and bone and cartilage toxicity, and biomarkers to detect the toxicity.
Introduction 44
The C-type natriuretic peptide (CNP) analog is one of the most expecting therapeutic 45 approaches to treat achondroplasia [1] . The binding of CNP to natriuretic-peptide receptor B 46 (NPR-B) inhibits fibroblast growth factor receptor 3 downstream signaling [2], recognized as 47 an important regulator of endochondral bone growth [3] . We recently reported that the 48 exogenous administration of CNP-53 has the potential to stimulate skeletal growth related to 49 short stature, and restore the skull morphology and size of foramen magnum in CNP-KO rats 50 [4, 5] . As a CNP derivative, a clinical trial utilizing BMN-111 is currently proceeding in 51 pediatric patients with achondroplasia [6] . We designed ASB20123, a CNP/ghrelin chimeric 52 peptide, as a novel peptide. ASB20123 contains the full-length 22-amino acids of human 53 CNP-22 fused to the 17-amino acids on the C-terminus region of human ghrelin, and the 54 single amino acid is substituted in its ghrelin region. This novel derivative demonstrated full 55 agonistic activity for NPR-B and showed significantly longer half-life in plasma compared 56 with the native forms. A significant and dose-dependent increase in body length was shown 57 in rats after 12 weeks of administration via subcutaneous infusion [7] . 58 CNP is produced in the brain, kidney, bone, blood cells, blood vessels, and heart [8] . 59 NPR-B is expressed in the brain, lung, bone, heart, and ovary tissue. It is also expressed at 60 relatively high levels in fibroblasts and vascular smooth muscle cells [9] . However, the 61 changes that occur after excessive exogenous CNP exposure remain to be clarified.
62
Furthermore, the toxicological profile of the CNP derivative has not been reported previously. 63 In the present study, we evaluated the exhaustive toxicological profile of ASB20123. 64 Furthermore, we researched the relationship between the specific bone and cartilage toxicity 65 and morphological changes of the epiphyseal plate and reliable biomarkers to detect the 66 toxicity. Twenty male and 20 female rats at 7 weeks of age were randomly divided into 4 groups each 94 with 5 males and 5 females. Dose levels were set at 0.5, 1.5, and 5.0 mg/kg/day. The control 95 animals were treated with the vehicle at the same dosing volume as the test article-treated 96 animals. The dosing volume was set at 1 mL/kg, and the dosing volume for each animal was 97 calculated based on the most recent body weight. Each animal was injected with the dosing 98 formulation subcutaneously once a day for 4 weeks into the back of the animals using a 99 disposable injection needle and syringe. The dose levels were selected based on the result of 100 previous study, in which the rats received at the dose of ASB20123 0.15 mg/kg/day for 12 101 weeks showed over-growth [7] .
102
Mechanism study (Study 2) 103 Fifteen male and 15 female rats at 12 months of age were randomly divided into 3 groups, 104 each with 5 males and 5 females. Dose levels were set at 0.5 and 5.0 mg/kg/day. Other 105 conditions and procedures were the same as those for study 1. Twenty-five male rats at 7 weeks of age were randomly divided into 5 groups with 5 males 108 each. Dose levels were set at 0.005, 0.05, 0.5, and 5.0 mg/kg/day. Other conditions and 109 procedures were the same as those for study 1. were examined with an auto-analyzer (7170, Hitachi Ltd., Japan), and the sodium, potassium, 129 and chloride were examined with an electrolyte analyzer (EA07, A&T Corporation, Japan).
130

ALP isozymes and osteocalcin 131
The remaining serum samples collected for blood chemistry were used for the serum ALP 132 isozyme and osteocalcin measurement. For ALP isozyme measurement, the auto (Fig 1) . 165 The results of histopathological examination are shown in S1 table, and representative some animals with the epiphyseal plate, but these findings were not observed in animals with 215 a closed epiphyseal plate (Table 1) between the appearance of bone toxicity and body or femur lengths was not observed (Fig 4) .
237
The results for the other observations and examination items were similar to those of study 1. 
